Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes

British Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2005, Pages 199-206

  Glaeser, H ^a,b,d   Drescher, S ^a   Eichelbaum, M ^a   Fromm, M F ^a,c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytochrome P450 2C; Cytochrome P450 3A4; Enterocytes; Human small intestine; Rifampicin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MESSENGER RNA; NORVERAPAMIL; RIFAMPICIN; VERAPAMIL;

ADULT; ARTICLE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME METABOLISM; ENZYME REGULATION; EX VIVO STUDY; HOMOGENATE; HUMAN; HUMAN TISSUE; INCUBATION TIME; INTESTINE CELL; MALE; METABOLITE; NORMAL HUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADMINISTRATION, ORAL; ADULT; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; ENTEROCYTES; ENZYME INHIBITORS; HUMANS; MALE; RIFAMPIN; RNA, MESSENGER;

EID: 13444249728     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02265.x     Document Type: Article

References (43)

1. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000; 12 (1): 3-12.
2. Watkins PB. The barrier function of CVP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27 (2-3): 161-70.
3. Zhang V, Benet LZ. The gut as a barrier to drug absorption, combined role of cytochrome P450, 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40 (3), 159-68.
4. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60 (1): 14-24.
5. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338 (8781): 1488-90.
6. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90 (5): 1871-8.
7. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J Clin Invest 1999; 104 (2): 147-53.
8. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et al. Induction of P-glycoprotein by rifampicin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68 (4): 345-55.
9. Langhoff E, Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment. Lancet 1983; 2 (8357): 1031.
10. Backman JT, Kivisto KJ, Olkkola KJ, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54 (1): 53-8.
11. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996; 24 (4): 796-801.
12. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KJ. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42 (9): 819-50.
13. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampicin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162 (9): 985-92.
14. Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. Effects of erythromycin or rifampicin on losartan pharmacokinetics in healthy subjects. Clin Pharmacol Ther 1998; 63 (3): 316-23.
15. Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1975; 9 (2-3): 219-27.
16. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69 (6): 400-6.
17. Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985; 20 (4): 323-6.
18. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampicin drug interaction in humans. Clin Pharmacol Ther 1987; 42 (4): 388-94.
19. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45 (1): 27-9.
20. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986; 22 (1): 49-53.
21. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31 (4): 421-31.
22. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29 (3): 242-51.
23. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampicin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299 (3): 849-57.
24. Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002; 302 (2): 475-82.
25. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309 (1): 303-9.
26. von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001; 70 (3): 217-27.
27. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73 (3): 223-31.
28. Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, et al. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 2002; 71 (3): 131-40.
29. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450, 3A mRNA. Drug Metab Dispos . 2002; 30 (10), 1108-14.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227 (259): 680-5.
31. Klempnauer KH, Bonifer C, Sippel AE. Identification and characterization of the protein encoded by the human c-myb proto-oncogene. Embo J 1986; 5 (8): 1903-11.
32. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450, 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353 (1), 116-21.
33. von Richter O, Eichelbaum M, Schonberger F, Hofmann U. Rapid and highly sensitive method for the determination of verapamil, [2H7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 738 (1): 137-47.
34. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253 (1): 387-94.
35. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80 (4): 1029-36.
36. Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13 (9): 565-75.
37. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450. function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43: 149-73.
38. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26 (2): 144-60.
39. Lapple F. Charakterisierung der Expression und Induzierbarkeit Von Arzneimittelmetabolisierenden Enzymen der CYP2C-Subfamilie in Humanen Geweben. Stuttgart: University of Stuttgart; 2000.
40. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1-23.
41. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampicin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157 (5): 1575-80.
42. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycopcotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75 (3): 172-83.
43. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 1998, 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci . 87 (11), 1322-30.